ERBB2 and gastric cancer: Trastuzumab was also the first targeted agent approved as standard treatment for HER2-positive advanced GC based on the results of the ToGA trial.40 In the ToGA trial, it was found that there existed primary and secondary resistance to HER2 blockage in GC patients.